{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a&page=8", "query": { "intervention": "Pegylated interferon alfa-2a", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 199, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:43:50.534Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03575208", "title": "Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "hepatitis B immune globulin (HBIg)", "type": "BIOLOGICAL" }, { "name": "Pegylated interferon alfa (pegIFN)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-02-13", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575208" }, { "nct_id": "NCT00637923", "title": "Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2008-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2014-02-10", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 10, "location_summary": "Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Largo", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00637923" }, { "nct_id": "NCT00537407", "title": "A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Debio 025", "type": "DRUG" }, { "name": "Peg-IFNα2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 50, "start_date": "2007-09", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 7, "location_summary": "La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00537407" }, { "nct_id": "NCT01273064", "title": "Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "CTS-1027", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Conatus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2011-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2012-06-11", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273064" }, { "nct_id": "NCT01448044", "title": "Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BMS-790052 (NS5A Replication Complex Inhibitor)", "type": "DRUG" }, { "name": "Placebo matching BMS-790052", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2011-12", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 4, "location_summary": "San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more", "locations": [ { "city": "San Clemente", "state": "California" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Annandale", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448044" }, { "nct_id": "NCT01225380", "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection" ], "interventions": [ { "name": "GS-9190", "type": "DRUG" }, { "name": "GS-9256", "type": "DRUG" }, { "name": "Pegasys®", "type": "BIOLOGICAL" }, { "name": "Copegus®", "type": "DRUG" }, { "name": "GS-9190 placebo", "type": "DRUG" }, { "name": "GS-9256 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 324, "start_date": "2010-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225380" }, { "nct_id": "NCT02407080", "title": "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Polycythemia Vera", "Essential Thrombocythemia" ], "interventions": [ { "name": "RG7388", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-04", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407080" }, { "nct_id": "NCT01369199", "title": "Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "Entecavir and peginterferon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2012-05", "completion_date": "2017-02-14", "has_results": true, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 20, "location_summary": "Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369199" }, { "nct_id": "NCT00882193", "title": "Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Hepatitis C", "Genotype 1", "Relapse" ], "interventions": [ { "name": "Betaine", "type": "DRUG" }, { "name": "Peginterferon alpha 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 2, "start_date": "2009-05-01", "completion_date": "2011-01-12", "has_results": false, "last_update_posted_date": "2023-11-30", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882193" }, { "nct_id": "NCT01516918", "title": "A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "VX-222", "type": "DRUG" }, { "name": "telaprevir", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "peginterferon-alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 103, "start_date": "2012-02", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-10-14T09:43:50.534Z", "location_count": 28, "location_summary": "Birmingham, Alabama • San Diego, California • Englewood, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01516918" } ] }